Kamber, C; Zimmerli, Stefan; Suter, Franziska Marta; Müller, Beatrice Ursula; Mansouri Taleghani, Behrouz; Betticher, Daniel; Zander, T; Pabst, Thomas (2015). Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone marrow transplantation, 50(4), pp. 573-578. Nature Publishing Group 10.1038/bmt.2014.290
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
bmt2014290a.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (403kB) |
The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. Disease burden due to HZ was assessed as high or rather high in 70% of the patients. By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation (P=0.009). Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ (P=0.007). Our data indicate that VZV reactivation after ASCT is a frequent event carrying a significant disease burden and it is associated with improved survival. Low levels of specific VZV antibodies at ASCT suggest increased vulnerability for VZV reactivation.Bone Marrow Transplantation advance online publication, 19 January 2015; doi:10.1038/bmt.2014.290.
Actions (login required)
 |
Edit item |